Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) was the recipient of some unusual options trading activity on Thursday. Investors acquired 2,770 call options on the company. This is an increase of approximately 311% compared to the typical daily volume of 674 call options.
Insider Activity
In related news, CEO Ian Mortimer acquired 30,000 shares of the stock in a transaction dated Wednesday, September 30th. The stock was bought at an average price of $37.38 per share, with a total value of $1,121,400.00. Following the completion of the transaction, the chief executive officer directly owned 49,923 shares of the company’s stock, valued at approximately $1,866,121.74. The trade was a 150.58% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Thomas Patrick Kelly acquired 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, September 30th. The shares were bought at an average price of $37.32 per share, for a total transaction of $559,800.00. Following the completion of the acquisition, the chief financial officer owned 15,000 shares of the company’s stock, valued at $559,800. This trade represents a ? increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Corporate insiders own 2.91% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Xenon Pharmaceuticals in the 2nd quarter valued at approximately $454,057,000. Jupiter Topco LLC acquired a new position in Xenon Pharmaceuticals during the second quarter worth $252,673,000. Janus Henderson Group PLC raised its position in Xenon Pharmaceuticals by 2.3% during the first quarter. Janus Henderson Group PLC now owns 4,175,982 shares of the biopharmaceutical company’s stock worth $242,858,000 after acquiring an additional 91,948 shares in the last quarter. Affinity Asset Advisors LLC raised its position in Xenon Pharmaceuticals by 34.0% during the first quarter. Affinity Asset Advisors LLC now owns 1,675,000 shares of the biopharmaceutical company’s stock worth $97,401,000 after acquiring an additional 425,000 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Xenon Pharmaceuticals by 23.6% in the third quarter. Pictet Asset Management Holding SA now owns 1,468,072 shares of the biopharmaceutical company’s stock valued at $54,612,000 after acquiring an additional 280,349 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.
Xenon Pharmaceuticals Trading Down 1.9%
Shares of Xenon Pharmaceuticals stock traded down $0.72 during trading hours on Thursday, reaching $37.03. 243,523 shares of the company’s stock were exchanged, compared to its average volume of 1,385,516. The company has a 50 day moving average of $39.88 and a two-hundred day moving average of $52.08. Xenon Pharmaceuticals has a fifty-two week low of $33.38 and a fifty-two week high of $72.66. The stock has a market cap of $3.58 billion, a P/E ratio of -7.89 and a beta of 0.11.
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.02. As a group, analysts expect that Xenon Pharmaceuticals will post -4.63 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
XENE has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating on shares of Xenon Pharmaceuticals in a research report on Friday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research report on Friday, October 2nd. JPMorgan Chase & Co. cut their target price on Xenon Pharmaceuticals from $82.00 to $80.00 and set an “overweight” rating on the stock in a research note on Tuesday. Wells Fargo & Company reduced their price target on Xenon Pharmaceuticals from $69.00 to $64.00 and set an “overweight” rating for the company in a research report on Friday, September 18th. Finally, Royal Bank Of Canada decreased their price target on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, September 18th. Eleven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $71.15.
Check Out Our Latest Analysis on XENE
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.
See Also
- Five stocks we like better than Xenon Pharmaceuticals
- The Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
